

Creation Date 18-Sep-2012 Revision Date 18-Sep-2012 Revision Number 1

# SECTION 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

**Product Identifier** 

Product Description: 2',3'-Dideoxycytidine

Cat No. 449500000; 449501000; 449505000

**Synonyms** DDC; Zalcitabine

Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Laboratory chemicals
Uses advised against No Information available

Details of the supplier of the safety data sheet

Company

Acros Organics BVBA
Janssen Pharmaceuticalaan 3a

2440 Geel, Belgium

**E-mail address** begel.sdsdesk@thermofisher.com

**Emergency Telephone Number** 

For information in the US, call: 001-800-ACROS-01 For information in Europe, call: +32 14 57 52 11

Emergency Number, Europe: +32 14 57 52 99 Emergency Number, US: 001-201-796-7100

CHEMTREC Phone Number, US: 001-800-424-9300 CHEMTREC Phone Number, Europe: 001-703-527-3887

#### **SECTION 2. HAZARDS IDENTIFICATION**

Classification of the substance or mixture REGULATION (EC) No 1272/2008

Carcinogenicity Category 2

Classification according to EU Directives 67/548/EEC or 1999/45/EC

For the full text of the R-phrases and H-Statements mentioned in this Section, see Section 16

Symbol(s) Xn - Harmful

**R-phrase(s)** R40 - Limited evidence of a carcinogenic effect

**Label Elements** 

\_\_\_\_\_



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

#### **SECTION 2. HAZARDS IDENTIFICATION**



Signal Word Hazard Statements Warning

H351 - Suspected of causing cancer

Precautionary Statements - EU (§28, 1272/2008)

P280 - Wear protective gloves/ eye protection/ face protection

P281 - Use personal protective equipment as required

P202 - Do not handle until all safety precautions have been read and understood

P308 + P313 - IF exposed or concerned: Get medical advice/ attention

#### Other Hazards

No information available.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Component	EC-No.	Weight %	CAS-No	67/548/EEC Classification	CLP Classification - Regulation (EC) No 1272/2008	REACH No.
2',3'-Dideoxycytidine (aids initiative) 7481-89-2		>95	7481-89-2	Xn;R40	Carc. 2 (H351)	-

For the full text of the R-phrases and H-Statements mentioned in this Section, see Section 16

### **SECTION 4. FIRST AID MEASURES**

**Description of first aid measures** 

**Eye Contact** Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Obtain

medical attention.

**Skin Contact** Wash off immediately with plenty of water for at least 15 minutes. Get medical attention

immediately if symptoms occur.

**Ingestion** Do not induce vomiting. Call a physician or Poison Control Center immediately.



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

**Inhalation**Move to fresh air. If breathing is difficult, give oxygen. Do not use mouth-to-mouth resuscitation

if victim ingested or inhaled the substance; induce artificial respiration with a respiratory

medical device. Get medical attention immediately if symptoms occur.

Notes to Physician Treat symptomatically

#### **SECTION 5. FIRE-FIGHTING MEASURES**

#### **Extinguishing media**

#### **Suitable Extinguishing Media**

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

#### Extinguishing media which must not be used for safety reasons

No information available.

#### Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors

#### Advice for fire-fighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear. Thermal decomposition can lead to release of irritating gases and vapors.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

#### Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Use personal protective equipment. Avoid dust formation.

#### **Environmental precautions**

Should not be released into the environment.

#### Methods and material for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dust formation.

#### **SECTION 7. HANDLING AND STORAGE**

#### **Precautions for Safe Handling**

Wear personal protective equipment. Ensure adequate ventilation. Avoid contact with skin, eyes and clothing. Avoid dust formation. Do not breathe dust. Use only under a chemical fume hood.

#### Conditions for safe storage, including any incompatibilities

Keep refrigerated. Keep container tightly closed in a dry and well-ventilated place.

#### **Specific End Uses**



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Control parameters** 

Exposure limits This product, as supplied, does not contain any hazardous materials with occupational

exposure limits established by the region specific regulatory bodies.

Legend:

Group 1 - Carcinogenic to Humans

Group 2A - Probably Carcinogenic to Humans Group 2B - Possibly Carcinogenic to Humans

Biological limit values This product, as supplied, does not contain any hazardous materials with biological limits

established by the region specific regulatory bodies.

Derived No Effect Level (DNEL)
Predicted No Effect Concentration

(PNEC)

No information available. No information available.

Safety glasses with side-shields

**Exposure controls** 

Engineering Measures Ensure adequate ventilation, especially in confined areas Ensure that eyewash stations and

safety showers are close to the workstation location

Personal protective equipment

Eve Protection

Hand Protection

Skin and body protection

Protective gloves

Wear appropriate protective gloves and clothing to prevent skin exposure

**Respiratory Protection**Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits

are exceeded or if irritation or other symptoms are experienced

Hygiene Measures Handle in accordance with good industrial hygiene and safety practice

**Environmental exposure controls** No information available.

#### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State Solid Appearance White

pH No information available.

Boiling Point/Range No information available.

Melting Point/Range216 - 220°C / 420.8 - 428°FFlash PointNo information available.Autoignition TemperatureNo information available.

Water Solubility

Molecular Formula

Water Solubility

Soluble

C9 H13 N3 O3

Molecular Weight 211.22

### **SECTION 10. STABILITY AND REACTIVITY**



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity

**Chemical Stability** 

Stable under normal conditions.

Possibility of Hazardous Reactions

Hazardous Polymerization

Hazardous polymerization does not occur.

Hazardous Reactions .

None under normal processing..

**Conditions to Avoid** 

Avoid dust formation, Incompatible products, Excess heat.

**Incompatible Materials** 

Acids, Bases.

**Hazardous Decomposition Products** 

Carbon monoxide (CO). Carbon dioxide (CO<sub>2</sub>). Nitrogen oxides (NOx).

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

#### **Information on Toxicological Effects**

**Acute Toxicity** 

Product Information No acute toxicity information is available for this product

**Component Information** 

**Chronic Toxicity** 

Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen R40

- Limited evidence of a carcinogenic effect

Component

2',3'-Dideoxycytidine (aids

initiative)

IARC	UK
Group 2B	

Legend:

Group 1 - Carcinogenic to Humans

Group 2A - Probably Carcinogenic to Humans

Group 2B - Possibly Carcinogenic to Humans

SensitizationNo information available.Mutagenic EffectsNo information available



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

\_\_\_\_\_

**Reproductive Effects**No information available. **Developmental Effects**No information available.

Target Organs None known.

Other Adverse Effects The toxicological properties have not been fully investigated. See actual entry in RTECS for

complete information

Endocrine Disruptor Information None known

### **SECTION 12. ECOLOGICAL INFORMATION**

**Toxicity** 

**Ecotoxicity effects** Do not empty into drains

Persistence and degradability

No information available

Bioaccumulative potential

No information available.

Componentlog Pow2',3'-Dideoxycytidine (aids initiative)-1.32

Mobility in soil

No information available.

Results of PBT and vPvB assessment

Other adverse effects

No information available

### **SECTION 13. DISPOSAL CONSIDERATIONS**

Waste treatment methods

Waste from Residues / Unused

**Products** 

Dispose of in accordance with local regulations

Contaminated Packaging Empty containers should be taken to local recyclers for disposal

### **SECTION 14. TRANSPORT INFORMATION**

IMDG/IMO Not regulated

ADR Not regulated

IATA Not regulated



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

#### **SECTION 14. TRANSPORT INFORMATION**

#### **SECTION 15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **International Inventories**

Component	EINECS	ELINCS	NLP	TSCA	DSL	NDSL	PICCS	ENCS	CHINA	AICS	KECL
2',3'-Dideoxycytidine (aids	-	-		-	Χ	-	-	-	-	-	=
initiative)											

#### Legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**CHINA** - China Inventory of Existing Chemical Substances

**AICS** - Inventory of Chemical Substances

**KECL** - Existing and Evaluated Chemical Substances

#### **Chemical Safety Assessment**

#### **SECTION 16. OTHER INFORMATION**

#### Full text of R-phrases referred to under sections 2 and 3

R40 - Limited evidence of a carcinogenic effect

Revision Date 18-Sep-2012

**Revision Summary** 

Reason for revision Not applicable

This safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006

Disclaimer

The information provided on this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered as a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other material or in any process, unless specified in the text.



2',3'-Dideoxycytidine Revision Date 18-Sep-2012

**End of Safety Data Sheet**